Revenue segments as reported by the company.

Technology & Analytics Solutions

Research & Development Solutions

Contract Sales & Medical Solutions

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Depreciation and amortization

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IQVIA Hlds

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IQVIA reports solid Q4 performance, addresses macro challenges proactively

IQVIA delivered a strong performance in Q4 2022 with revenue growth, operational achievements, and solid financial guidance for 2023, underlining its market position and strategic focus.
While facing challenges from macroeconomic factors, wage inflation, and market conditions, the company is proactively addressing these issues through cost-cutting measures and debt reduction strategies.
By leveraging its strengths in stable operations, record bookings, and financial discipline, IQVIA aims to navigate challenges, capitalize on opportunities, and drive sustainable growth in the future.

IQVIA reports solid Q1 growth amidst industry challenges and opportunities

IQVIA Hlds (IQV) Q1 2023 reflects strong financial performance and operational resilience.
Challenges in backlog burn and industry dynamics are being managed effectively.
Opportunities in M&A activity and demand for real-world evidence drive growth.
Steady guidance for 2023 positions the company well for future success.

IQVIA posts strong Q2 results, eyes growth amid AI investments

IQVIA's Q2 performance reflects solid growth and strategic wins in data and analytics solutions.
While facing challenges in decision delays and economic uncertainties, the company's AI investments and strong R&DS segment offer growth opportunities.
With a focus on leveraging AI across business areas and a vast patient data advantage, IQVIA is well-positioned for future success.

IQVIA reports mixed Q3 results, eyes growth through strategic initiatives

IQVIA's Q3 2023 performance showcased strength in R&DS bookings and revenue growth, while TAS faced challenges from foreign exchange and weak demand. The company aims to drive growth through new contracts, cost reduction initiatives, and strategic pricing adjustments, with a focus on stabilizing performance and pursuing growth opportunities in 2024.

IQVIA reports robust Q4 earnings, eyes growth amid challenges

IQVIA's strong performance in bookings and revenue growth positions it well for future success.
While facing challenges in TAS and pricing negotiations, IQVIA's contract wins and guidance for 2024 show resilience.
Opportunities lie in improving demand for TAS, increasing RFPs, and growth in the data business.
Overall, IQVIA's strategic wins and financial outlook indicate a positive trajectory for the company.

IQVIA reports solid Q1 performance, eyes growth through partnerships

IQVIA delivered a solid performance in Q1 2024, meeting revenue expectations and showcasing growth in bookings and pipeline. The company's strengths lie in technology-enabled solutions, global partnerships, and public health initiatives.
Challenges include cancellations impacting revenue, pricing pressures, and the need to navigate market dynamics. However, IQVIA's opportunities in innovation, partnerships, and market expansion position it well for future growth.
Overall, IQVIA's strategic focus on technology, client engagements, and public health initiatives, amidst challenges in cancellations and pricing pressures, presents a resilient outlook. The company's financial performance and industry leadership are key strengths.
With a proactive approach to challenges and a focus on seizing opportunities, IQVIA remains well-positioned for sustained growth and success in the evolving healthcare landscape. The company's adaptability and strategic initiatives drive confidence in its future prospects.

IQVIA reports robust Q2 earnings, eyes growth amidst market challenges

IQVIA Hlds delivered a strong Q2 performance with revenue and earnings growth, supported by efficient operations and solid financial metrics.
While facing challenges such as pricing pressures and market dynamics, the company remains optimistic about future opportunities and growth potential.
Strategic focus on addressing challenges and seizing opportunities will be key to sustaining performance and maximizing shareholder value in the dynamic healthcare landscape.

IQVIA Hlds reports Q3 growth, faces study delays and pricing challenges

IQVIA Hlds demonstrated solid financial performance in Q3 2024, driven by revenue growth and increased EPS.
While facing challenges like study delays and pricing pressures, the company's strategic strengths and opportunities for growth remain intact.
With a focus on share buybacks and R&DS growth, IQVIA is positioning itself for sustained success in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

IQVIA (IQV) delivered earnings and revenue surprises of 12.38% and 4.80%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

IQVIA Holdings (IQV) Q2 Earnings and Revenues Beat Estimates

Shares of IQVIA Holdings (NYSE:IQV) fell 1.6% in pre-market trading after the company reported Q2 results.

IQVIA Holdings: Q2 Earnings Insights

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.

IQVIA Appoints Ron Bruehlman Executive Vice President and interim Chief Financial Officer

IQVIA and JDRF Collaborate to Improve Understanding of Type 1 Diabetes Using Real World Data

IQVIA's (IQV) second-quarter 2020 results are likely to reflect coronavirus-led decline in the top and bottom lines.

IQVIA (IQV) to Report Q2 Earnings: What's in the Cards?

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) has announced its collaboration with AstraZeneca (LON: AZN) to accelerate development of a potential new vaccine for COVID-19. This joint initiative is part of the U.S. government’s recently announced Operation Warp Speed project. Operation Warp Speed is part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The specific IQVIA

IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE: IQV) today announced its strategic alliance with LMC Manna Research, the largest network of fully owned and integrated clinical research sites in Canada, to launch IQVIA’s first Prime Site in Canada. This adds to our network of more than 980 Prime and Partner clinical sites globally, which are sites with special designation assuring pharmaceutical and biotech companies their clinical trials will take place in premier

IQVIA Collaborates with LMC Manna Research to Launch the Largest Clinical Investigation Site in Canada

Amgen

Anthem

Bristol-Myers

Guardant Health Inc

Iovance Biotherapeutics

Medtronic

Veeva Systems

West Pharmaceutical Services

Acceleron Pharma

The pandemic has put the health care industry under a global spotlight.

10 Stocks to Invest in the Health Care Revolution

Solid technological suite and growth opportunities from emerging markets are positives for IQVIA Holdings (IQV). However, higher interest expense, seasonality and foreign exchange rate risks persist.

Here's Why You Should Hold IQVIA Holdings (IQV) Stock Now

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?

Why Is IQVIA (IQV) Up 2.6% Since Last Earnings Report?

IQVIA Holdings, Inc. (IQV) CEO Ari Bousbib on Q1 2020 Results - Earnings Call Transcript

Shares of IQVIA Holdings (NYSE:IQV) rose 1.3% after the company reported Q1 results.

IQVIA Holdings: Q1 Earnings Insights

IQVIA's (IQV) first-quarter 2020 revenues increase year over year while earnings decline.

IQVIA (IQV) Beats on Q1 Earnings, Revenues, Lowers '20 View

IQVIA (IQV) delivered earnings and revenue surprises of 1.35% and 1.38%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

IQVIA Holdings (IQV) Q1 Earnings and Revenues Beat Estimates

IQVIA Holdings (IQV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy IQVIA Holdings (IQV) Ahead of Earnings?

Equifax

Interpublic Group of Companies

Robert Half Int.

S&P Global

TriNet Group

TransUnion

Here's a sneak peek of how four business service stocks are placed prior to the respective earnings releases on Apr 28.

Business Services Apr 28 Earnings Rooster: SPGI, IQV & More

IQVIA's (IQV) first-quarter 2020 revenues are likely to have benefited from strength across Research & Development Solutions, Technology & Analytics Solutions and Contract Sales & Medical Solutions.

IQVIA (IQV) to Report Q1 Earnings: What's in the Cards?

IQVIA Holdings (IQV) witnesses global site closures and disruptions in operations, which require face-to-face dealings, in the wake of coronavirus outbreak.

IQVIA Holdings (IQV) Lowers Q1 Guidance on Coronavirus Scare

Headwinds from COVID-19 may negatively impact 2020 projections.

Is IQVIA Holdings Stock a Buy?

IQVIA (IQV) Down 31.8% Since Last Earnings Report: Can It Rebound?

IQVIA Holdings Inc. (IQV) CEO Ari Bousbib on Q4 2019 Results - Earnings Call Transcript

IQVIA's (IQV) fourth-quarter 2019 earnings and revenues increase year over year.

IQVIA (IQV) Surpasses Q4 Earnings and Revenue Estimates

IQVIA (IQV) delivered earnings and revenue surprises of 1.16% and 1.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

IQVIA Holdings (IQV) Q4 Earnings and Revenues Surpass Estimates

IQVIA's (IQV) fourth-quarter 2019 earnings and revenues are likely to have increased year over year.

IQVIA (IQV) to Report Q4 Earnings: What's in the Cards?

IQVIA (IQV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

News for IQVIA Hlds Stock (IQV)